Sign Out
Atogepant is not recommended in patients with severe hepatic impairment (see Dosage & Administration).
Excipients with known effect: AQUIPTA tablets 10 mg contain less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'.
AQUIPTA tablets 60 mg contain 31.5 mg sodium per tablet, equivalent to 1.6% of the WHO recommended maximum daily intake of 2 g sodium for an adult.
Effects on ability to drive and use machines: Atogepant has no or negligible influence on the ability to drive and use machines. However, it may cause somnolence in some patients. Patients should exercise caution before driving or using machinery until they are reasonably certain that atogepant does not adversely affect performance.
Continue with Google